Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Evaluation of the Effects of Equicoaching on Social Reintegration Among Young Adults Who Have Been Treated for Cancer

NCT07515274 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-04-05
Last updated
2026-04-13

Condition(s) studied

Cancer Pediatric

Investigational drug(s) / intervention(s)

equicoaching

equicoaching: An initial individual interview will be organized with each participant to discuss their experience of the disease, their social relationships, their leisure activities, their relationship with horses, and their relationship with sports, exploring their experiences and practices in physical activities. Questionnaires to assess quality of life, well-being, and self-confidence will be completed during this interview. This will be followed by equicoaching. This intervention will be carried out by two qualified professionals over a period of six months and will consist of six monthly group sessions combined with individual follow-up. This will be followed by equicoaching. This intervention will be carried out by two qualified professionals over a period of six months and will consist of six monthly group sessions combined with monthly individual follow-up via videoconference. The various group sessions will address different topics. After each group session, the AJAs will have individual i

Study summary

This is a category 2 human research study (RIPH), interventional, single-center, prospective, open-label.

The primary objective of this study is to qualitatively assess the effects of equicoaching on social reintegration in young adults who have been treated for cancer.

The secondary objectives are to evaluate the contribution of equicoaching to:

1. Self-confidence;
2. Well-being
3. Quality of life Satisfaction with equicoaching will also be evaluated.

Eligibility

Sex
ALL
Min age
15 Years
Max age
25 Years
Healthy volunteers
No
Inclusion Criteria: * Have been treated for a malignant oncological or hematological condition. * Be between 15 and 25 years of age at the time of cancer diagnosis. This age range corresponds to that chosen by the Leon Berard Cancer Center (CLB) and the Institute of Pediatric Hematology and Oncology (IHOPe) for the Adolescents and Young Adults with Cancer (DAJAC) program * Have been treated at IHOPe/CLB as part of the DAJAC program * Have completed intensive treatment within the last twelve months. * Be able to understand, read, and write French * Be affiliated with a health insurance plan * Have been informed about the study and have given consent For minors: * All of the above criteria * Parent/legal guardian informed about the study and having given consent Exclusion Criteria: * Patient deprived of liberty by judicial or administrative decision * Pregnant or breastfeeding women

Primary outcome measure(s)

  • social reintegration — Inclusion and month 6
    Social reintegration will be assessed using a qualitative comparative analysis of two individual semi-structured interviews conducted at baseline and six months after the intervention. Interview topics will include illness trajectory, social and family relationships, level of autonomy and independence, ability to plan for the future, social participation, and participants' perceptions of the equicoaching intervention. All interviews will be audio-recorded, transcribed verbatim, and analyzed using thematic analysis with NVivo software to identify changes in themes and subthemes over time.

Trial sites (1)

FacilityCityRegionStatus
CLB Lyon France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07515274 on ClinicalTrials.gov ↗ ← All trials in France